J&J Rybrevant/Lazcluze study shows superiority over Tagrisso

Johnson & Johnson (NYSE:JNJ) reported that longer-term data from a Phase 3 study of a combination of its drugs Rybrevant and Lazcluze showed a favorable overall survival trend compared to AstraZeneca’s (AZN) Tagrisso in the treatment of certain type of lung cancer.

The study, called MARIPOSA, showed that at three years of treatment, with a median follow up of 31.1 months, 61% of patients given the combination were alive, compared with 53% of those treated with Tagrisso, also known as osimertinib, according to a statement.

The combination is being evaluated in patients with advanced non-small cell lung cancer with epidermal growth factor receptor, also known as EGFR, exon 19 deletions or L858R substitution mutations.

J&J added that overall survival was continuing to be assessed, with longer-term follow-up as a key secondary endpoint. It added that the primary efficacy outcome measure was progression-free survival.

Lazcluze, also known as lazertinib, was co-developed by J&J and YuHan. The FDA approved the combination of Lazcluze and Rybrevant for the treatment of EGFR-mutated non-small cell lung cancer in late August.